

DAFTAR PUSTAKA

1. Rolling T, Hohl TM, Zhai B. Minority report: the intestinal mycobiota in systemic infections. *Curr Opin Microbiol*. 2020;56:1–6.
2. Hilmar W, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US Hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis*. 2004;39:309–17.
3. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the Intensive Care Unit. *Crit Care*. 2008;12:1–9.
4. Lee RA, Zurko JC, Camins BC, Griffin RL, Martin Rodriguez J, McCarty TP, *et al*. Impact of infectious disease consultation on clinical management and mortality in patients with candidemia. *Clin Infect Dis*. 2019;68:1585–7.
5. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, *et al*. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006). *Crit Care Med*. 2009;37:1612–8.
6. Eggimann P, Garbino J, Didier P. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. *Lancet Infect Dis*. 2003;3:685–702.
7. World Health Organization. Coronavirus Situation Reports. 2022. Diunduh dari: <http://www.who.int/emergencies/disease/novel-coronavirus-2019/situation-reports> 25 Maret 2022
8. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y *et al*. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507–13.
9. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, *et al*. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of The Lombardy Region, Italy. *JAMA - J Am Med Assoc*. 2020;323:1574–81.
10. Garcia-vidal C, Sanjuan G, Moreno-garcía E, Puerta-alcalde P, Garcia-pouton N, Chumbita M, *et al*. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect*. 2021;27:83–8.
11. Mastrangelo A, Germinario BN, Ferrante M, Frangi C, Voti RL, Muccini C, *et al*. Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls. *Clin Infect Dis*. 2021;73:e2838–9.
12. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, *et al*. Worrisome trends in incidence and mortality of candidemia in Intensive Care Units (Paris area, 2002-2010). *Intensive Care Med*. 2014;40:1303–12.
13. Gong X, Luan T, Wu X, Li G, Qiu H, Kang Y, *et al*. Invasive candidiasis in Intensive Care Units in China: risk factors and prognoses of Candida albicans and non-albicans Candida infections. *Am J Infect Control*. 2016;44:e59–63.

14. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? *Clin Infect Dis*. 2001;33:1959–67.
15. BJ Kullberg MA. Invasive candidiasis external. *N Engl J Med*. 2015;373:1445–56.
16. Lo HJ, Köhler JR, Didomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous *C. albicans* mutants are avirulent. *Cell*. 1997;90:939–49.
17. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Adherence and biofilm formation of non-*Candida albicans* *Candida* species. *Trends Microbiol*. 2011;19:241–7.
18. Loss SH, De Oliveira RP, Maccari JG, Savi A, Boniatti MM, Hetzel MP, *et al*. The reality of patients requiring prolonged mechanical ventilation: A multicenter study. *Rev Bras Ter Intensiva*. 2015;27:26–35.
19. Falcone M, Tiseo G, Tascini C, Russo A, Sozio E, Raponi G, *et al*. Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. *Eur J Intern Med*. 2017;41:33–8.
20. Poissy J, Damonti L, Bignon A, Khanna N, Von Kietzell M, Boggian K, *et al*. Risk factors for candidemia: A prospective matched case-control study. *Crit Care*. 2020;24:1–11.
21. Pulcrano G, Iula DV, Vollaro A, Tucci A, Cerullo M, Esposito M, *et al*. Rapid and reliable MALDI-TOF mass spectrometry identification of *Candida* non-*albicans* isolates from bloodstream infections. *J Microbiol Methods*. 2013;94:262–6.
22. Ahmad S, Khan Z. Invasive candidiasis: A review of nonculture-based laboratory diagnostic methods. *Indian J Med Microbiol*. 2012;30:264–9.
23. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, *et al*. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. *Clin Infect Dis*. 2015;62:e1–50.
24. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: the role of nsp2 and nsp3 in its pathogenesis. *J Med Virol*. 2020;92:584–8.
25. Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Ciccozzi M, Pascarella S. Sars-CoV-2 envelope and membrane proteins: structural differences linked to virus characteristics?. *Biomed Res Int*. 2020;2020:4389089.
26. Yang S, Lee GWM, Chen CM, Wu CC, Yu KP. The size and concentration of droplets generated by coughing in human subjects. *J Aerosol Med Depos Clear Eff Lung*. 2007;20:484–94.
27. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy. *Environmental Res*. 2020;188:1–18.
28. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 μm . *J Aerosol Sci*. 1986;17:811–25.
29. Bourouiba L. Turbulent gas clouds and respiratory pathogen emissions: potential implications for reducing transmission of COVID-19. *JAMA - J Am Med Assoc*. 2020;323:1837–8.

30. Doremalen N van, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, *et al.* Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med.* 2020;382:1564–7.
31. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181:271-280.e8.
32. Yang N, Shen HM. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. *Int J Biol Sci.* 2020;16:1724–31.
33. Ralph A. Tripp SMT. Host factors in coronavirus replication. *Cur Top Microbiol.* 2018;419:1–42.
34. Perrier A, Bonnin A, Desmarests L, Danneels A, Goffard A, Rouillé Y, *et al.* The C-terminal domain of the MERS corona virus M protein contains a trans-golgi network localization signal. *J Biol Chem.* 2019;294:14406–21.
35. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. *Eur J Intern Med.* 2020;76:14–20.
36. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, *et al.* Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *J Med Virol.* 2020;92:491–4.
37. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun.* 2020;109:102433.
38. Organization WH. Coronavirus Disease Symptoms. 2022. Diunduh dari: https://www.who.int/health-topics/coronavirus#tab=tab_3 14 Februari 2022
39. Peng QY, Wang XT, Zhang LN. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic. *Intensive Care Med.* 2020;46:849–50.
40. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, *et al.* Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *N Engl J Med.* 2020;382:2081–90.
41. T Li, C Wei, W Li, F Hongwei JS. Pneumonia of novel coronavirus infection “diagnosis and treatment proposal.” *Med J Peking Union Med Coll Hosp.* 2020;9:29.
42. Arendrup M, Horn T, Frimodt-Møller N. In vivo pathogenicity of eight medically relevant *Candida* species in an animal model. *Infection.* 2002;30:286–91.
43. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.* 2020;8:420–2.
44. Seagle EE, Jackson BR, Lockhart SR, Georgacopoulos O, Nunnally NS, Roland J, *et al.* The landscape of candidemia during the coronavirus disease 2019 (COVID-19) pandemic. *Clin Infect Dis.* 2022;74:802–11.
45. Arastehfar A, Shaban T, Zarrinfar H, Roudbary M, Ghazanfari M, Hedayati MT, *et al.* Candidemia among iranian patients with severe COVID-19 admitted to ICUs. *J Fungi.* 2021;7:1–9.

46. Omrani AS, Koleri J, Ben Abid F, Daghfel J, Odaippurath T, Peediyakkal MZ, *et al.* Clinical characteristics and risk factors for COVID-19-associated Candidemia. *Med Mycol.* 2021;59:1262–6.
47. Coskun AS, Durmaz SO. Fungal infections in COVID-19 Intensive Care Patients. *Polish J Microbiol.* 2021;70:395–400.
48. Macauley P, Epelbaum O. Epidemiology and mycology of candidaemia in non-oncological medical intensive care unit patients in a Tertiary Center in the United States: overall analysis and comparison between non-COVID-19 and COVID-19 cases. *Mycoses.* 2021;64:634–40.
49. Bishburg E, Okoh A, Nagarakanti S, Lindner M, Migliore C, Patel P. Fungemia in COVID-19 ICU patients, a single medical center experience. *J Med Virol.* 2021;93:2810–4.
50. Kayaaslan B, Eser F, Kaya Kalem A, Bilgic Z, Asilturk D, Hasanoglu I, *et al.* Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. *Mycoses.* 2021;64:1083–91.
51. Nucci M, Barreiros G, Guimarães LF, Deriquehem VAS, Castiñeiras AC, Nouér SA. Increased incidence of candidemia in a Tertiary Care Hospital with the COVID-19 pandemic. *Mycoses.* 2021;64:152–6.
52. Arastehfar A, Carvalho A, Hong Nguyen M, Hedayati MT, Netea MG, Perlin DS, *et al.* Covid-19-associated candidiasis (Cac): An underestimated complication in the absence of immunological predispositions? *J Fungi.* 2020;6:1–13.
53. Hammarskjöld F, Mernelius S, Andersson RE, Berg S, Hanberger H, Löfgren S, *et al.* Possible transmission of *Candida albicans* on an Intensive Care Unit: Genotype and temporal cluster analyses. *J Hosp Infect.* 2013;85:60–5.
54. Kaur H, Chakrabarti A. Strategies to reduce mortality in adult and neonatal candidemia in developing countries. *J Fungi.* 2017;3:41.
55. Nathania E, Widjaja JT. Candidiasis as secondary infection in post COVID-19: a new problem? *J Respirasi.* 2021;7:127.
56. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. *Jama.* 2020;323:1239–42.
57. Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzone B, Codda G, *et al.* Bloodstream infections in critically ill patients with COVID-19. *Eur J Clin Invest.* 2020;50:e13319.
58. Riche CVW, Cassol R, Pasqualotto AC. Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids?. *J Fungi.* 2020;6:1–4.
59. Chowdhary A, Tarai B, Singh A, Amit S. Infections in critically ill coronavirus disease patients, India, april-july 2020. *Emerg Infect Dis.* 2020;26:2694–6.
60. Gong Y, Li C, Wang C, Li J, Ding M, Chen D, *et al.* Epidemiology and mortality-associated factors of invasive fungal disease in elderly patients: A 20-year retrospective study from Southern China. *Infect Drug Resist.* 2020;13:711–23.

61. Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: A narrative review. *J Fungi*. 2021;7:921.
62. Posteraro B, Torelli R, Vella A, Leone PM, De Angelis G, De Carolis E, *et al.* Pan-echinocandin-resistant candida glabrata bloodstream infection complicating COVID-19: A fatal case report. *J Fungi*. 2020;6:1–11.
63. Hostetter MK. Handicaps to host defense. Effects of hyperglycemia on C3 and *Candida albicans*. *Diabetes*. 1990;39:271–5.
64. Ruiz GO, Osorio J, Valderrama S, Álvarez D, Díaz RE, Calderón J, *et al.* Risk factors for candidemia in non-neutropenic critical patients in Colombia. *Med Intensiva*. 2016;40:139–44.
65. Keighley CL, Pope A, Marriott DJE, Chapman B, Bak N, Daveson K, *et al.* Risk factors for candidemia: A prospective multi-centre case-control study. *Mycoses*. 2021;64:257–63.
66. Pyrgos V, Ratanavanich K, Donegan N, Veis J, Walsh TJ, Shoham S. *Candida* bloodstream infections in hemodialysis recipients. *Med Mycol*. 2009;47:463–7.
67. Alves J, Palma P, Azevedo D, Rello J. Candidemia in the patient with malignancy. *Hosp Pract*. 2018;46:246–52.
68. Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, *et al.* Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?. *Autoimmun Rev*. 2020;19:102564.
69. McCarty T. Candidaemia and Severe COVID-19—Which Risk Factors are Modifiable. *Clin Infect Dis*. 2021;74:812–3.
70. Meawed TE, Ahmed SM, Mowafy SMS, Samir GM, Anis RH. Bacterial and fungal ventilator associated pneumonia in critically ill COVID-19 patients during the second wave. *J Infect*. 2021;14:1375–80.
71. Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. *Pediatr Infect Dis J*. 2000;19:822–7.
72. Chakraborti A, Jaiswal A, Verma PK, Singhal R. A Prospective study of fungal colonization and invasive fungal disease in long-term mechanically ventilated patients in a Respiratory Intensive Care Unit. *Indian J Crit Care Med*. 2018;22:597–601.
73. Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R, Quan TP, *et al.* A *Candida auris* outbreak and its control in an Intensive Care Setting. *N Engl J Med*. 2018;379:1322–31.
74. Tóth R, Nosek J, Mora-Montes HM, Gabaldon T, Bliss JM, Nosanchuk JD, *et al.* *Candida parapsilosis*: From genes to the bedside. *Clin Microbiol Rev*. 2019;32:1–38.
75. Walsh TJ, Katragkou A, Chen T, Salvatore CM, Roilides E. Invasive candidiasis in infants and children: Recent advances in epidemiology, diagnosis, and treatment. *J Fungi*. 2019;5:11.
76. Delfino D, Scordino F, Pernice I, Lo Passo C, Galbo R, David A, *et al.* Potential association of specific *Candida parapsilosis* genotypes, bloodstream infections and colonization of health workers' hands. *Clin Microbiol Infect*. 2014;20:O946–51.

77. Mattos-silva P, Felix NS, Silva PL, Robba C, Battaglini D, Pelosi P, *et al.* Pros and cons of corticosteroid therapy for COVID-19 patients. *Respir Physiol.* 2020;280:103492.
78. Segrelles-Calvo G, De Saraújo GR, Frases S. Systemic mycoses: A potential alert for complications in COVID-19 patients. *Future Microbiol.* 2020;15:1405–13.
79. Sosale A, Sosale B, Kesavadev J, Chawla M. Steroid use during COVID-19 infection and hyperglycemia—What a physician should know. *Diabetes Metab.* 2021;15:102167.
80. Salehi M, Ahmadikia K, Mahmoudi S, Kalantari S, Jamalimoghadamshahkhalil S, Izadi A, *et al.* Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: species identification and antifungal susceptibility pattern. *Mycoses.* 2020;63:771–8.
81. Revankar SG. Candidiasis (Invasive). *MSD Manual.* 2021. Diunduh dari: <https://www.msdmanuals.com/en-sg/professional/infectious-diseases/fungi/candidiasis-invasive> 23 Januari 2022
82. Hoenigl M. Invasive fungal disease complicating coronavirus disease 2019: when it rains, it spores. *Clin Infect Dis.* 2021;73:e1645–8.
83. Marr KA, Platt A, Tornheim JA, Zhang SX, Datta K, Cardozo C, *et al.* Aspergillosis complicating severe coronavirus disease. *Emerg Infect Dis.* 2021;27:18–25.
84. Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, *et al.* The microbial coinfection in COVID-19. *Appl Microbiol Biotechnol.* 2020;104:7777–85.
85. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. *Nat Rev Dis Prim.* 2018;4:1–20.
86. Gonzalez-Lara MF, Ostrosky-Zeichner L. Update on the diagnosis of candidemia and invasive candidiasis. *Curr Fungal Infect Rep.* 2019;13:301–7.
87. CDC. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. 2021. Diunduh dari: <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html> 14 Februari 2022
88. Al-Hatmi AMS, Mohsin J, Al-Huraizi A, Khamis F. COVID-19 associated invasive candidiasis. *J Infect.* 2021;82:e45–6.
89. White L, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, *et al.* A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. *SSRN Electron J.* 2020;73:e1634–44.
90. Carpio ALM, Climaco A. Fungemia candidiasis. *StatPearls;* 2021.
91. Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, *et al.* T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. *Sci Transl Med.* 2013;5:1–8.
92. Pfeiffer CD, Samsa GP, Schell WA, Reller LB, Perfect JR, Alexander BD. Quantitation of *Candida* CFU in initial positive blood cultures. *J Clin Microbiol.* 2011;49:2879–83.
93. Rajni E, Singh A, Tarai B, Jain K, Shankar R, Pawar K, *et al.* A high frequency of *Candida auris* blood stream infections in coronavirus disease 2019 patients admitted to Intensive Care Units, Northwestern India: a case control study. *Open Forum Infect Dis.* 2021;8:ofab452.

94. Clancy CJ, Nguyen MH. Diagnosing invasive candidiasis. *J Clin Microbiol.* 2018;56:1–9.
95. Lanternier F, Mahdavian SA, Barbati E, Chaussade H, Koumar Y, Levy R, *et al.* Inherited CARD9 deficiency in otherwise healthy children and adults with meningo-encephalitis and/or colitis caused by *Candida*. *J Allergy Clin Immunol.* 2015;135:1558–68.
96. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: Systematic review and meta-analysis. *J Clin Microbiol.* 2011;49:665–70.
97. Solomkin JS, Simmons RL. *Candida* infection in surgical patients. *World J Surg.* 1980;4:381–92.
98. Tang M, Yang J, Li Y, Zhang L, Peng Y, Chen W, *et al.* Diagnostic accuracy of MALDI-TOF mass spectrometry for the direct identification of clinical pathogens from urine. *Open Med.* 2020;15:266–73.
99. Lagacé-Wiens PR, Adam HJ, Karlowsky JA, Nichol KA, Pang PF, Guenther J, *et al.* Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: Analysis of performance, cost, and turnaround time. *J Clin Microbiol.* 2012;50:3324–8.
100. Patel R. A moldy application of MALDI: MALDI-ToF mass spectrometry for fungal identification. *J Fungi.* 2019;5:4.
101. Robert MG, Cornet M, Hennebique A, Rasamoelina T, Caspar Y, Pondérand L, *et al.* Maldi-tof ms in a medical mycology laboratory: On stage and backstage. *Microorganisms.* 2021;9:1–16.
102. Tokak S, Uğurcan D, Tekindal M. Determination of candidemia risk factors in inpatients in adult Intensive Care Unit. *FLORA.* 2020;25:47–53.
103. Cortés J, Montañez A, Carreño-Gutiérrez A, Reyes P, Gómez C, Pescador A. Risk factors for mortality in Colombian patients with candidemia. *J Fungi.* 2021;7:442.
104. Chen CY, Sheng WH, Huang SY, Chou WC, Yao M, Tang JL, *et al.* Clinical characteristics and treatment outcomes of patients with candidaemia due to *Candida parapsilosis sensu lato* species at a medical centre in Taiwan, 2000-12. *J Antimicrob Chemother.* 2014;70:1531–8.
105. Zhang Z, Zhu R, Luan Z, Ma X. Risk of invasive candidiasis with prolonged duration of ICU stay: A systematic review and meta-analysis. *BMJ Open.* 2020;10:e036452.
106. Niyas VK, Rahulan SD, Arjun R, Sasidharan A. ICU-acquired Candidemia in COVID-19 Patients: An Experience from a Tertiary Care Hospital in Kerala, South India. *Indian J Crit Care Med.* 2021;25:1207–8.
107. Denny S, Abdolrasouli A, Elamin T, Gonzalo X, Charani E, Patel A, *et al.* A retrospective multicenter analysis of candidaemia among COVID-19 patients during the first UK pandemic wave. *J Infect.* 2021;82:276–316.
108. Garey KW, Turpin RS, Bearden DT, Pai MP, Suda KJ. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. *Int J Antimicrob Agents.* 2007;29:557–62.

109. Lin KY, Chen PY, Chuang YC, Wang JT, Sun HY, Sheng WH, *et al.* Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis. *J Infect.* 2018;77:242–8.
110. Kato H, Yoshimura Y, Suido Y, Shimizu H, Ide K, Sugiyama Y, *et al.* Mortality and risk factor analysis for *Candida* blood stream infection: A multicenter study. *J Infect Chemother.* 2019;25:341–5.
111. Guimarães T, Nucci M, Mendonça JS, Martinez R, Brito LR, Silva N, *et al.* Epidemiology and predictors of a poor outcome in elderly patients with candidemia. *Int J Infect Dis.* 2012;16:442–7.
112. Motta FA, Dalla-Costa LM, Muro MD, Cardoso MN, Picharski GL, Jaeger G, *et al.* Fatores de risco de mortalidade por candidemia em crianças internadas. *J Pediatr (Rio J).* 2017;93:165–71.

